Korean Market
EXCH
Prestige BioPharma
★

Corporate Governance Report Filed: Non-compliance with Korean Best Practices Due to Singapore Incorporation, No Shareholder Return Policy

 
PERI
Prestige BioPharma
★

Prestige BioPharma Reports Revenue Growth but Continues Operating Loss; Net Loss Widens Due to Impairment on Subsidiary Investment